Teva, Celltrion partner to commercialise two biosimilar candidates

Teva and Celltrion on Thursday announced a partnership to jointly commercialise two of the latter's investigational biosimilars in the US and Canada. The products are CT-P10, a proposed biosimilar version of Roche and Biogen's Rituxan (rituximab), and CT-P6, an experimental biosimilar version of Roche's Herceptin (trastuzumab). Siggi Olafsson, CEO of Teva Global Generic Medicines, remarked "the introduction of two additional [monoclonal antibody] biosimilar candidates into our near-term pipeline bolsters our biosimilar portfolio and continues to leverage Teva's unique cross-functional capabilities across both specialty and generic medicines." 

Under the agreed terms, Teva will pay Celltrion $160 million upfront, of which up to $60 million is refundable or creditable under certain circumstances. The companies will split profits from the commercialisation of the biosimilars candidates.

According to the companies, the Israeli drugmaker will hold responsibility for all commercial activities in the US and Canada following regulatory approval, while Celltrion will be responsible for all clinical development and regulatory activities. 

Both CT-P10 and CT-P6 are in late-stage development. Last year, Celltrion submitted CT-P10 for regulatory approval in the EU (for related analysis, read ViewPoints: Celltrion submits CT-P10, a proposed biosimilar rituximab, to European regulators, but the endgame remains unclear), while the company said it is preparing to submit CT-P6 for marketing authorisation in Europe in the current quarter.  

To read more Top Story articles, click here.